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Abstract
Background: COPD is a highly complex disease to manage as patients show great variation in symptoms and
limitations in daily life. In the last decade self-management support of COPD has been introduced as an effective
method to improve quality and efficiency of care, and to reduce healthcare costs. Despite the urge to change
the organisation of health care and the potential of eHealth to support this, large-scale implementation in daily
practice remains behind, especially in the Netherlands.
Methods/Design: We designed a multilevel study, called e-Vita, to investigate different organisational implementation
methods of a self-management web portal to support and empower patients with COPD in three different primary care
settings. Using a parallel cohort design, the clinical effects of the web portal will be assessed using an interrupted times
series (ITS) study design and measured according to changes in health status with the Clinical COPD Questionnaire
(CCQ). The different implementations and net benefits of self-management through eHealth on clinical outcomes will
be evaluated from human, organisational, and technical perspectives.
Discussion: To our knowledge this is the first study to combine different study designs that enable simultaneous
investigation of clinical effects, as well as effects of different organisational implementation methods whilst
controlling for confounding effects of the organisational characteristics. We hypothesize that an implementation
with higher levels of personal assistance, and integrated in an existing care program will result in increased use of
and satisfaction with the platform, thereby increasing health status and diminishing exacerbation and hospitalisation.
Trial registration: NTR4098 (31-07-2013)
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Background
Chronic obstructive pulmonary disease (COPD) repre-
sents one of the main causes of morbidity and mortality,
and worldwide nearly 3 million people die from COPD
every year [1]. In the Netherlands, COPD was respon-
sible for almost 5 % of the total deaths in 2011 [2]. More
than 3 million people died worldwide of COPD in 2012,
which is equal to 6 % of all deaths globally that year [3].
COPD is a highly complex disease to manage as patients
show great variation in symptoms and limitations in
daily life. This results in a position in the top ten of most
expensive diseases for respiratory disease [2]. Within the
last decade self-management support of COPD has been
introduced as an effective method to improve quality and
efficiency of care, and to reduce healthcare costs [4–6]. It
has shown to improve the level of recognition of severe ex-
acerbations [7]. Interventions to support self-management
have shown reductions in hospital admissions and fewer
sick days as a result of exacerbations [8, 9]. Studies have
shown that eHealth interventions are effective in stimulat-
ing self-management. Patients are better able to cope with
their illness at the time and place of their choosing, allow-
ing them to adapt their lifestyle to their condition while
eHealth support also reduces medical staff consultations
[10]. The deployment of eHealth applications facilitates
accessibility to healthcare, which in turn enhances the
patients’ understanding of their disease, sense of control,
and willingness to engage in self-management [11, 12].
Although patients’ attitudes and receptiveness towards
eHealth applications are promising in certain groups of
age and education [13–15], large-scale adoption of eHealth
in daily practice is low. Despite the urge to change the
organisation of health care and the potential of eHealth
to support this, large-scale implementation in daily
practice remains behind on predictions, especially in
the Netherlands [16].
Low adoption of eHealth in daily practice may be ex-
plained by the varying successes of eHealth programmes
[17–20]—sometimes with a negative impact on quality
of care and clinical effects [21]. In addition, the field of
eHealth assessment is relatively new. The evaluation of
eHealth research has a number of difficulties regarding
evaluation methods and challenges of technology itself
(usability and privacy), environmental issues that pose
special problems for eHealth researchers, and logistic or
administrative concerns of the selected evaluation method
[11]. Therefore specific frameworks have been developed
for eHealth evaluation, including evaluation of eHealth
over time and based on different development stages. For
example, Kaufman et al. [22] suggest that evaluation of
eHealth includes specification and needs of requirements,
component development, integration of components, in-
tegration in clinical setting and routine use. There are also
frameworks that suggest that eHealth should be evaluated
from different point of views. For example, Yusof et al.
[23] suggest that human, organisational, and technological
aspects and net benefits are essential components of
eHealth evaluation.
eHealth shows great potential for effective COPD man-
agement. Despite the difficulties of evaluation, research of
eHealth interventions is highly valuable for further adop-
tion of eHealth in daily practice. Positive as well as negative
results are needed to improve quality, utility and effective-
ness, to minimize the likelihood of harm, to promote
innovation, conserve resources, encourage participation, to
promote confidence among users, and to promote a posi-
tive public image [24]. Therefore we designed a multilevel
study to investigate implementation of a self-management
web portal to support patients with COPD in primary care.
As the web portal provides continuous education and
contact with health care professionals, we expect it to help
patients to better recognize and self-manage exacerbations
in an early phase, and thereby increase health status and
diminish exacerbation and hospitalisation. In this ongoing
study, called e-Vita, we compare different organisational
implementation methods in different primary care settings.
We aim to investigate 1) the effect of self-management
through eHealth on clinical outcomes and 2) the relation-
ship between technological and organisational factors on
the one hand and system use and user satisfaction on the
other hand. We will therefore evaluate implementation
and net benefits from human, organisational and technical
perspectives (Fig. 1).
We expect to publish the first results at the end of 2016.
Methods/Design
Our primary aim is to investigate the effect of use of
patient portals on clinical outcomes in primary care
COPD patients (net benefits, Fig. 1). In addition, we
aim to investigate the optimal organisational imple-
mentation method of the platform. Therefore we will
compare different organisational implementation methods
in different care settings, and evaluate their use and user
satisfaction. We hypothesize that an implementation setup
with greater personal support, integrated into an existing
care programme will be preferred by patients and there-
fore be more likely to be used.
As discussed in the introduction, the evaluation of
eHealth is a challenge because of the different views to
evaluate from (clinical, technical, and organisational).
Moreover, eHealth is not a classical clinical isolated
intervention (in this case a platform) with one output
(here CCQ). Instead it affects care processes, communica-
tion and patients behaviour, Finally we have a multilevel
purpose to not only investigate effects but also organisa-
tional implementation methods. Therefore we made a de-
sign for a quality improvement intervention. In this study
we aimed to include the importance of integration in the
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daily practice of primary care. Therefore we chose an
implementation study [25]. We designed a method to
promote the uptake of our research findings into routine
primary healthcare; with this design we aim at studying
the influences on healthcare professionals and patient be-
haviour and at evaluating the process by which effects are
achieved.
Because the most powerful studies are prospective stud-
ies, we chose a prospective parallel cohort design. We
asked three primary care groups to invite their COPD pa-
tients for the e-Vita study. Because there are several differ-
ences between the groups (Fig. 3), we can not compare
the COPD cohorts by combining data across three differ-
ent groups. We chose for an interrupted time series (ITS)
design to evaluate clinical outcomes (CCQ) within each
group. In ITS studies, data are collected at multiple time
points before and after an intervention in order to detect
whether or not the intervention has a significantly greater
effect than any underlying secular trend [26]. ITS can
detect changes that are delayed or intermittent. It can also
determine if the change is permanent or temporary.
In addition, it allows evaluation of variables which are
changing before the intervention, for instance, by compar-
ing slopes of trend lines before and after the intervention.
Finally, ITS makes it easier to control for confounding
variables and regression to the mean [27]. The ITS will be
performed according to guidelines of the EPOC Cochrane
group [25]. Although well-conducted randomised trials
provide the most reliable evidence on the effectiveness of
interventions, they are not feasible for our setting of an
implementation design with organisational changes in a
real-life health care system within three different care
groups with different demands. An advantage of an ITS
design is that it allows for the statistical investigation
of potential biases in the estimate of the effect of the
intervention.
In addition to clinical outcomes, we also want to investi-
gate the effect of different organisational implementation
methods. Therefore we will implement the platform in
group 1 and 2 using different methods. Differences will be
measured using a parallel cohort design. To be certain
that intervention groups will be balanced in known and
unknown prognostic factors in the long run we will use
randomisation within group 1 and 2. To rule out
Fig. 1 Model based on Yusof [22]: different aspects of eHealth evaluation
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human influences we will randomise online for the
level of support.
In this study we combine different study methods
within one research to investigate organisational imple-
mentation methods and net benefits of eHealth interven-
tions from human, organisational, and technical view. To
do so, we created a unique study that enables us to simul-
taneously investigate clinical effects, as well as effects of
different organisational implementation methods whilst
controlling for confounding effects on an organisational
level. In Fig. 2 the combined study design is shown.
Organisational and technical differences are depicted
in Fig. 2: three different care groups and two different
web portals are included. Two different methods of imple-
mentation are distinguished within group 1 and 2: one
with high level of personal assistance and one with low
level of personal assistance. All patients in group 1 and 2
start with a personal instruction by the primary care nurse
during a regular control visit. Patients will be randomly
subdivided in two groups by computer by research assis-
tants (randomisation is computerised to prevent human
influence) with high (a) and low (b) level of support. In
group 1a, high level support implies home visits for pa-
tients by a research nurse who accompanies the use of the
web portal. In group 2a, high level support implies tele-
phone consultation for patients by a research nurse who
accompanies use of the web portal. In group 1b and 2b
low level support implies that the primary care nurse
shows the patient only once how to use the web portal
(the usual organisational implementation method in daily
practice) without any follow-up instruction. In group 3
the web portal is offered as free use: patients will re-
ceive instructions from the web portal itself. There
will be no active support from caregivers or research
nurses.
The groups differ in organisation, area, use of the web
portal, and integration of the portal in a COPD disease
management program (Fig. 3); these characteristics are
based on Dutch reports of care groups [28]:
1. Group 1 will start with COPD disease management
simultaneous to implementation of the web portal.
The web portal is integrated in the disease
management program (integrated use).
2. Group 2 is used to working with a COPD disease
management program. They will start with the web
portal, which is integrated in their own disease
management program (integrated use).
3. Group 3 is used to working with a COPD disease
management program. They will start with the web
portal, but the web portal is not integrated in their
own disease management program (free use).
As was described above, the implementation of the
portal will be studied using a prospective parallel cohort
design. The clinical effects of the web portal will be in-
vestigated using an interrupted times series (ITS) study
design (Fig. 4) and measured according to changes in
health status with the Clinical COPD Questionnaire (CCQ,
see Appendix 1). ITS design includes multiple observations
over time that are ‘interrupted’ by interventions. The time
intervals between the observations T1, T2, T3, and T4 are
6 months, to detect the change in CCQ in a trend and
slope over the total period of time. The time intervals be-
tween the 3 measurements of each observation T1, T2, T3,
and T4 is 2 weeks, based on the high responsiveness of
CCQ [29]. The ITS will be performed according to guide-
lines of the EPOC Cochrane group [30]. The aim of an ITS
design is to detect confounding trends by performing sev-
eral measurements at specified time intervals, before and
Fig. 2 Research design for the different groups and interventions of e-Vita COPD
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after the intervention. An advantage of an ITS design is
that it allows for the statistical investigation of potential
biases in the estimate of the effect of the intervention.
Participants
Three health care groups participate in this study. There-
fore, COPD patients of general practices in these care
groups are eligible. More specifically, patients are eligible
when they are diagnosed with COPD according to GOLD
criteria (post-bronchodilator FEV1/FVC < 0.7) in accord-
ance with the Dutch general practitioners (GPs) COPD
Guidelines [31] and when they are treated for COPD in
primary care. The study is intended to be inclusive rather
than exclusive to achieve high external validity (applicabil-
ity to daily practice). Patients are excluded if they are un-
able to fill in questionnaires, patients that have no access
to internet, patients with terminal illness, immobile pa-
tients and patients with severe substance abuse.
Recruitment of patients and non-participation analysis
We started by recruiting primary care groups; group 1,
group 2, and group 3 decided to participate in this study
because they wanted to contribute to a project with a
possible healthcare improvement. The general practitioners
that are part of the care groups could volunteer to partici-
pate in the study; a selection of them did.
Because general practices as well as patients are free
to volunteer, bias might occur in our research group.
We will determine the differences in clinical status between
study participants (included patients) and non-participants
(eligible patients) by CCQ questionnaire, as well as gender
and age differences.
Intervention
In Fig. 5 all actions of the intervention are summarized:
1. In group 1 all caregivers (GPs as well as practice
nurses) will be trained to provide COPD care
Fig. 3 The different characteristics of Group 1, 2, and 3
Fig. 4 ITS design with CCQ
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according to an evidence based disease management
program; subsequently they implement the COPD
care program in their practices under supervision of
a specialized nurse. Practice nurses will receive
support by a research nurse to make sure their
records of COPD patients are up-to-date and to
prepare consultation with their patients according to
the disease management program. In addition, all
practice nurses will be trained to use the web portal
and to communicate with patients according to the
principles of self-management.
2. In group 2 all caregivers (GPs as well as practice
nurses) will be trained shortly to ameliorate their
skills in COPD care according to an evidence based
disease management program that they already use.
All practice nurses will be trained to use the web
portal and to communicate with patients according
to the principles of self-management. The training is
developed and provided for by the e-Vita study
group and is based on national and international
guidelines.
3. In group 3 caregivers will not receive any training.
Patients will receive a brochure how to use the web
portal.
The type of intervention is adopted by the care groups
after thorough consideration and discussion. The e-Vita
study group determined the type of platform and the
level of support.
Next, we will offer patients an online interactive care
platform or web portal. The portal provides disease spe-
cific education and tips that fit their personal disease
management program. In addition, the portal provides
tools to report and monitor personal health goals, actions
and health-related quality of life that can be shared with
the patients’ own practice nurses. The portal in group 1
and 2 has better quality and more advanced possibilities
for monitoring health goals with actions than the portal
in group 3. The portal will be provided for a period of
15 months. Patients are informed by letter about the
web portal. Patients in group 3 who agree to use the
portal will receive instructions and log in information
by e-mail. Patients in group 1 and 2 who agree to use
the portal will be invited by their own practice nurses
for intake. During intake the practice nurse defines a
personal health goal together with the patient and gives
instructions how and why to use the portal. Participants
continue to receive regular COPD care by their GP and
nurse practitioner according to the disease manage-
ment program of the care group. Stable COPD patients
visit their nurse practitioner yearly to check up on their
disease management. The patient portal can be used by
care professionals to prepare consultation or to monitor
patients in-between their visits to their general practice.
Fig. 5 Interventions per group
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Third, a subgroup of participants (1a and 2a) will re-
ceive extra support to use the portal by home visits or
with instructions by telephone. During the home visit
and consultation it will be checked if patients are able
to log on the portal, if they understand the possibilities
of the portal, and if they have started working on their
personal health goal using the portal.
Data collection
Data collection consists of self reporting questionnaires that
are integrated in the portal. Therefore all data collection is
provided digitally. In Fig. 6 the measurement schedule is vi-
sualized. There are four measurements in this study during
a period of 16 months. Due to the ITS design, CCQs will
be offered three times at each measurement.
Outcome parameters
Primary outcome
The primary outcome is clinical and expressed as health
status, measured using the CCQ. The CCQ was origin-
ally designed by Van der Molen and consist of 10 items
with a 7-point Likert scale. The CCQ comprises 3 domains;
symptom state (4 items), functional state (4 items) and
mental state (2 items). Research showed that the CCQ is a
reliable and valid questionnaire with Crohnbach’s alpha
between 0.89 and 0.91 [29].
Fig. 6 ITS measurements per interval
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Secondary outcomes
From the human perspective we will measure the following
outcomes:
Disability associated with breathlessness: this is
measured using the Medical Research Council (MRC)
breathlessness scale (see Appendix 2), which comprises
five statements that describe almost the entire range
of respiratory disability: from none (Grade 1) to almost
complete incapacity (Grade 5). It can predict survival
[32] and it is advocated as complementary to FEV1
in describing disability in those with COPD [33].
Quality of life (QoL): QoL will be assessed using EuroQol-
5D (EQ-5D). This questionnaire contains 5 items with a
3-point Likert scale. A higher score reflects higher quality
of life. The EQ-5D comprises 5 levels: mobility, self care,
daily activity, pain/discomfort and anxiety/depression.
Research showed that the EQ-5D is a reliable and valid
questionnaire [34]. The EQ-5D can be used to compute
QALY’s, which are necessary to evaluate cost-effectiveness.
Adoption of the portal: usage of the portal is monitored
continuously by log files. User satisfaction is measured
by purpose-designed questionnaires.
From the organisational perspective we will measure
the following outcome:
Costs: in this study we include direct costs of the
intervention and COPD care. Intervention costs
include development costs of the patient platform and
costs of the implementation process. Development
costs are provided retrospectively by the owner of the
portal. Implementation costs are administered by the
research group and mainly include costs of home visits
and interviews by telephone. The cost for COPD care
(time of professional care) is extracted from the portal
in which consultation in general practice will be
registered in an agenda. In addition, hospitalisation
(caused by COPD exacerbation) will be based on
reports of the patient and practice nurse in the portal.
All costs are based on regular tariffs in Dutch healthcare.
Determinants
Self-efficacy: self-efficacy is measured using the
Generalized Self-Efficacy Scale (GSES), which will be
displayed at baseline. This 10-item questionnaire was
designed in 1981 by Schwarzer [35]. The items are scored
on a four-point scale, in which a higher score reflects
higher self-efficacy. Research in 28 countries showed that
Cronbach’s alpha varies between .76 and .90, of which
mostly above .80. Self-efficacy is derived from the Social
Cognitive Theory, which states that behavioral change is
made possible by personal sense of control. Self-efficacy is
the “belief in one’s capabilities to organise and execute the
courses of action required to produce given attainments”.
Research shows that self-efficacy is an important factor for
self-management in behavioral change of the chronic ill,
such as diabetics and cardiovascular patients. For example,
in people with type 2 diabetes self-efficacy is an important
factor influencing self-management behaviours; self-
efficacy impacts adherence to treatment [36].
Sociodemographic characteristics: these are assessed by
a purpose-designed online questionnaire. We include
the following characteristics: age, socioeconomic status,
marital status, and general use of online and digital
products and services. Since decreased access to internet
and decreased general health outcomes have been
associated with lower socioeconomic status, minority
racial/ethnic groups, older age, and poorer health we
will include these characteristics in our study.
Power calculation
Health status of patients with COPD generally decreases
over time. Recent research on disease management pro-
grams in COPD in primary care shows that a general in-
crease of 1.5 to 2.0 points (SD 0.75) in CCQ can be
expected during a 1 year period [37]. In our study we offer
patients a web portal in addition to their regular disease
management program. We therefore expect that the regular
deterioration in CCQ (from 1.5 to 2.0 points) will change
to stabilisation of health status at 1.5 CCQ points. Hence,
we expect a significant difference in health status of 0.5
points in patients using the portal (2.0-1.5 = 0.5 points). To
measure significant differences in health status (>0.5 CCQ
points) at 80 % power, SD 0.75 and α = 0.05, 37 patients
must be included. Based on an estimated 20 % drop-out
during the study, 45 (37/0.80) patients are needed. As we
use two different organisational implementation methods
within two of the care groups 2*45 = 90 patients must be
included in those settings. In the third care group only one
organisational implementation method (free use) is used.
Hence, a total of 225 (90 + 90 + 45) patients are necessary
to achieve sufficient statistical power.
Data analysis
Along with our research design, analyses will be multilevel:
1. To investigate the effect of the use of the web portal on
the primary clinical outcomes, the ITS data will be
analysed. The preferred method to analyse ITS studies
is a statistical comparison of time trends before and
after the intervention. Time series analysis using
ARIMA models is one way of analysing the data, but
there are a number of statistical techniques that can be
used depending on the characteristics of the data, the
number of data points available and whether
autocorrelation is present. The final choice for the
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method to analyse the data will be made when the total
set of data is available after consultation of a statistician.
2. To investigate the effects of organisational aspects
uptake of the portal will be analysed for care group 1,
2 and 3 using Chi Square tests (Fishers’ Exact Test for
categorical variables and F-tests for continuous
variables) and (repeated measures) ANOVA analyses.
To analyse the effects of organizational aspects as
described in the paper, the groups will be compared.
3. To investigate the effect of integration of the web
portal in daily practice, outcomes within integrated
(group 1 and 2) and the free use groups (group 3) will
be analysed using Chi Square tests (Fishers’ Exact Test
for categorical variables and F-tests for continuous
variables) and (repeated measures) ANOVA analyses.
4. To investigate the effect of different organisational
implementation methods, outcomes within groups
with high level support (1a and 2a) and low level
support (1b, 2b and 3) will be analysed using Chi
Square tests (Fishers’ Exact Test for categorical
variables and F-tests for continuous variables) and
(repeated measures) ANOVA analyses.
5. To explore correlation between self efficacy,
sociodemographic characteristics on the one hand
and adoption of the portal and clinical outcomes on
the other hand, Pearson product-moment coefficients
will be calculated across all research groups.
6. To make a cost-effectiveness analysis, the direct costs of
the different organisational implementation methods
will be defined and analysed parallel to the effects of
the portal in terms of Quality of Life (EQ-5D).
Ethical principles
Participation in the study provides several benefits: increas-
ing costs and deficit of health care professionals stress the
need for efficient health care processes. Benefits of eHealth
regarding clinical effects and costs have repeatedly been
demonstrated, but extensive integration in clinical practice
stays behind. This projects aims to explore organisational
implementation methods for optimal integration of patient
portals in primary care. Optimal integration stimulates pa-
tients in self-management and improves efficiency and ac-
curacy administration and communication. We expect
patients to improve their health status while decreasing
health care use. Health care providers participating in these
projects improve communication between different
workers, adherence to guidelines, and thereby increase
quality of care. The online portals will not be offered to pa-
tients who are unable to use the online portals. However,
they will not be in disadvantage by receiving usual care.
Discussion
COPD is one of the main causes of morbidity and mortal-
ity in the world. Worldwide nearly 3 million people die
from COPD every year [1]. COPD is a highly complex dis-
ease to manage as patients show great variation in symp-
toms and limitations in daily life. An important treatment
of COPD is empowerment of patients: self-management
may reduce hospital admission and significantly improves
health status [38]; it can diminish the impact of exacerba-
tions on health status and tends to accelerate recovery
[39, 40]. eHealth tools for COPD patients have potential
to raise self-management to higher levels. Patients’ attitudes
and receptiveness towards eHealth applications are promis-
ing [20] but lack of robust trials and inconclusive research
results [17–20] make it impossible to draw firm conclusions
about clinical effectiveness or cost effectiveness.
In this study we aim to empower COPD patients in
primary care by providing a self-management web por-
tal. We expect this portal to help patients to better
recognize and self-manage exacerbations in an early
phase, thereby increasing health status and diminishing
exacerbation and hospitalisation. In addition we aim to
provide practical insights into a successful implementa-
tion of patients portals in real-life primary care settings.
We will therefore compare different organisational imple-
mentation methods. We expect that an implementation
setup with greater personal support will result in increased
use of the online program.
This e-Vita study has several strengths. To our know-
ledge this is the first study to combine different study
designs that enable simultaneous investigation of clinical
effects, as well as effects of different organisational imple-
mentation methods whilst controlling for confounding ef-
fects of the organisational characteristics. Our hypothesis
is that in well-organised primary care groups with highly
skilled and motivated nurses and doctors there will be a
higher use of the portal and therefore better health status.
Secondly, our web portal is integrated in real life care set-
tings and will therefore provide practical insights and
knowledge of eHealth in daily practice. Third, this study
adds Dutch evidence to the existing body of knowledge
which is important because local political and financial
factors have a major impact on successful integration in
daily practice [41]. This study also includes several limita-
tions: from a technical perspective the development of the
web portal is a difficult task due to lack of broad experi-
ence in the field. The technique of the web portal and de-
cisions made during the design phase will largely affect
our outcomes but are beyond the scope and influence of
our study. From a human perspective, effects through
self-management imply behavioural changes. Behavioural
changes require time, whereas the study period is limited to
15 months. Furthermore, patients in a primary care setting
have a low burden of disease. From an organisational per-
spective other projects in the primary care cooperation’s
can influence the speed and thoroughness of the imple-
mentation of our web portal.
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Table 1 Please circle the number of the response that best describes how you have been feeling during the past week. (Only one
response for each question)
During the past week, how often did you feel…
Never Hardly A few Several
times
Many
times
Most of
the time
All the time
1. Short of breath at rest? 0 1 2 3 4 5 6
2. Short of breath doing physical activities? 0 1 2 3 4 5 6
3. Concerned about your breathing getting worse? 0 1 2 3 4 5 6
4. Depressed (down) because of your breathing problems? 0 1 2 3 4 5 6
During the past week, how much of the time did you…
5. Cough 0 1 2 3 4 5 6
6. Produce phlegm? 0 1 2 3 4 5 6
During the past week, how limited were you in these activities because of your breathing problems when doing…
Not limited
at all
Very slightly
limited
Slightly
limited
Moderately
limited
Very
limited
Extremely
limited
Totally limited
or unable to do
7. Strenuous physical activities (such as climbing stairs,
hurrying, doing sports)?
8. Moderate physical activities (such as walking, housework,
carrying things)?
9. Daily activities at home (such as dressing, washing yourself)?
10. Social activities (such as talking, being with children, visiting
friends/relatives)?
Table 2
Do you ever experience breathlessness?
Which of the following statement applies most to you?
❍ I do not experience breathlessness 0
❍ I am only troubled by breathlessness during strenuous exercise 1
❍ I am only short of breath when hurrying on the level or walking
up a slight hill
2
❍ My breathlessness makes me walk slower on the level than most
people my age, or results in the need to stop for breath after
walking at my own pace after 15 min
3
❍ I need to stop for breath for a few minutes after walking 100 m
on the level
4
❍ I am too breathless to leave the house, or need to catch my
breath when undressing
5
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